NCT06062979 - Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

HIV

Interventions

DRUG

rilpivirine/cabotegravir

WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.

Trial Locations (2)

20009

Whitman-Walker 1525 Clinic, Washington D.C.

20032

Whitman-Walker Max Robinson Center, Washington D.C.